# TB-EM-053 — Protected Family Plan and Report Release

Milestone 2 ordered item 12/12. Predecessor: merged synthetic-only TB-EM-052 checkpoint [PR #151](https://github.com/NTinkicht/TheraBridge-Emergent/pull/151), squash commit `e5d9711af7cd7a5af05bbff7288297a212238229`.

## Status: PLANNING-ONLY DRAFT — NOT IMPLEMENTED / NOT TESTED / NOT AUTHORIZED

This work unit is approval-gated. It must not infer clinical, privacy, consent, safeguarding, legal, or release authority from the owner product-policy baseline or from operational synthetic demos. Professional attestations in [private policy PR #47](https://github.com/NTinkicht/TheraBridge/pull/47) remain pending; G2/G2b NO-GO and G3–G7 activation constraints remain unchanged. TB-EM-052 full executable transfer remains separately blocked by #115. This checkpoint changes no runtime API, release/recipient grants, consent decisions, assignment access, clinical signatures, media, deployment, or real-patient processing.

## Proposed scope after accountable authorization

1. Reconcile approved D7 purpose-specific guardian consent, D4 household restrictions, D-NEW-5 safeguarding holds and D1 signatures/step-up with existing Reports/Plans/Releases/Grants/Consent boundaries.
2. Define immutable provenance for clinician-signed clinical snapshots and per-recipient permitted release scopes; admin rights never grant clinical content access.
3. Implement atomic, version-bound authorization checks and revoke-capable recipient grants, ensuring tenant/child/specialty/purpose scope before any replay/idempotency result.
4. Test denial, stale versions, concurrent release/revocation, wrong household, blocked guardian/safeguarding cases, retry semantics, audit and full synthetic seven-role journeys.
5. Run six exact-head CI jobs and independent final code review. Never equate synthetic acceptance with clinical authorization or production deployment.

## Acceptance / activation boundary

**BLOCKED pending separately named clinical-governance, privacy/DPO, safeguarding, security, legal and consent/release owner signoffs.** No executable family clinical release or real-data activation may be merged from this draft without those approvals. Maintain TB-EM-052's outstanding full-transfer issue separately.
